Alantolactone Inhibits Double Expression Lymphoma via Dual-Targeted Glycogen Synthase Kinase 3 Beta and B-Cell Lymphoma2
Introduction Lymphomas represent 3.6% of global cancer burden, with diffuse large B-cell lymphoma (DLBCL) constituting the most common aggressive subtype in China.1–3 While the prednisone, vincristine, doxorubicin and cyclophosphamide (R-CHOP) regimen …